DexCom has delivered a mix of strong recent news and a complicated long term share price record, which puts the spotlight squarely on whether the current valuation lines up with the cash the business can generate. With the stock last closing at US$81.39, the key issue for you is how much of the story around its glucose monitoring franchise is already reflected in that price.
- Over the past 5 years, DexCom shareholders have seen the share price decline 49.8%, which makes the current valuation question less about momentum and more about what the cash flow profile can justify from here.
- Recent progress rolling out the G7 continuous glucose monitoring platform and securing broader use cases, including new approvals, can support expectations for future revenue streams and potentially influence how durable and scalable DexCom's cash flows look.
- If you'd rather focus on earnings, this one's for you. See why DexCom's 30.6x P/E tells a different valuation story.
The stock's next move may depend on whether today's price can be supported by DexCom's projected cash flows when they are run through a Discounted Cash Flow (DCF) view of its intrinsic value.
If you want to test whether this kind of cash flow valuation question shows up elsewhere in the market, apply the same lens to 31 high quality undervalued stocks.
Is DexCom a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at the cash DexCom can generate for shareholders and discounts it back to today. On this model, the business is treated as a growing cash generator, with latest twelve month free cash flow of about $1.0b and analyst projections that rise further in the coming decade.
The projections assume DexCom can keep expanding free cash flow from that $1.0b base, then slow into a more mature phase rather than shrink. That helps explain why the DCF outcome points to an estimated intrinsic value substantially above the current share price of US$81.39. Because the company recently reported strong Q3 2026 results and raised full year guidance, the gap suggests the market is still not pricing the cash flow outlook in line with the DCF model. Find out what DexCom could be worth using our Discounted Cash Flow (DCF) estimate.
The DexCom Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the DexCom valuation puzzle leaves off. They map out what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than today, and they sit on the platform's Community page. Rather than focusing on a single multiple or model output, each one lays out the key assumptions behind its fair value view so you can track those expectations against future reported results.
One of the top community narratives on DexCom: 31% undervalued
According to MarkoVT, a Simply Wall St Community investor who wrote this Narrative, DexCom’s recent earnings strength and valuation reset are pulling in fresh attention.
"DexCom has continued to reap the rewards stemming from positive Earnings and investors seeking appealing, undervalued stocks outside of memory chip / semiconductor companies..."
Discover why this Narrative puts DexCom at 31% undervalued.
One more piece of the DexCom puzzle to check
Cash flow projections only tell part of the story, because the people directing DexCom and how their pay is structured can heavily influence future decisions and risk. See who runs DexCom and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com